Showing 3811-3820 of 6950 results for "".
- Study Seeks to Evaluate V. Dox Technology's Ability to Improve Healing Following HS Surgical Procedurehttps://practicaldermatology.com/news/study-seeks-to-evaluate-v-dox-technologys-ability-to-improve-healing-following-hs-surgical-procedure/2460958/The first patient has been enrolled in a new study using Vomaris Innovations, Inc.’s s bioelectric antimicrobial wound care technology following surgical treatment for Hidradenitis Suppurativa (HS). When tunnels develop under the skin in HS, a surgical procedure called deroofing i
- FDA Approves Cyltezo as First Interchangeable Biosimilar with Humirahttps://practicaldermatology.com/news/fda-approves-cyltezo-as-first-interchangeable-biosimilar-with-humira/2460957/The FDA approved the supplemental Biologics License Application (sBLA) for Boehringer Ingelheim's Cyltezo (adalimumab-adbm) as the first Interchangeable biosimilar with Humira (adalimumab). The FDA originally approved Cyltezo in 2017 for the treatment of multiple chronic inflammatory diseases
- Study Highlights Skin Cancer Disparities in Hispanic/Latino Patientshttps://practicaldermatology.com/news/study-highlights-skin-cancer-disparities-in-hispaniclatino-patients/2460950/When Hispanic/Latino people are diagnosed with skin cancer, their tumors are 17 percent larger than tumors in non-Hispanic White patients, a new study shows. For the study, researchers analyzed a total of 3,486 Mohs micrographic surgeries of basal cell, squamous cell, and bas
- Safety Concerns Fuel Vaccine Hesitancy in PsO Patients on Biologics, But Data Fail to Show Increased Riskhttps://practicaldermatology.com/news/safety-concerns-fuel-vaccine-hesitancy-in-pso-patients-on-biologics-but-data-fail-to-show-increased-risk/2460947/Safety concerns and concerns about aggravation of their underlying condition are common drivers of COVID-19 vaccine hesitancy among patients with psoriatic disease, results of a new study show. Data come from an analysis of social media posts from patients in the US, UK, France, Germany, and
- Experts Highlight Need to Focus on Psoriasis Patients’ Wellbeing in Practicehttps://practicaldermatology.com/news/experts-highlight-need-to-focus-on-psoriasis-patients-wellbeing-in-practice/2460945/In addition to managing the clinical manifestations of psoriasis, clinical practices should implement an overall and holistic assessment of the wellbeing of each patient, says a panel of scientists speaking at a symposium during the European Association of Dermatology and Venereology (EADV) 30th&
- Updates from EADV: Cosentyx Autoinjector, Genetic Variants Linked to Genital Warts, At-Home PDT Shows Promisehttps://practicaldermatology.com/news/updates-from-eadv-cosentyx-autoinjector-genetic-variants-linked-to-genital-warts-at-home-pdt-shows-promise/2460939/• Treatment with Cosentyx®(secukinumab) 300mg in a 2mL autoinjector (UnoReady® pen) was more effective than placebo and achieved high patient satisfaction compared to two 150mg pre-filled syringes, according to Phase 3b data presented
- Happy 25th Birthday Restylane!https://practicaldermatology.com/news/happy-25th-birthday-restylane/2460928/Galderma’s Restylane is celebrating 25 years on the market. Since launching in Europe in 1996, Restylane has celebrated many milestones across the globe. This includes the first approval for use by the U.S. Food and Drug Administration (FDA) in 2003 and in China by the
- Nutrafol May Promote Hair Growth in Menopausal Womenhttps://practicaldermatology.com/news/nutrafol-may-promote-hair-growth-in-menopausal-women/2460923/Nutrafol may improve hair growth and quality for perimenopausal, menopausal, and postmenopausal women, according to research presented during The North American Menopause Society (NAMS) Annual Meeting in Washington, DC. Researchers compared results at 6 mont
- Soligenix to Advance Synthetic Hypericin Development in Psoriasishttps://practicaldermatology.com/news/soligenix-to-advance-synthetic-hypericin-development-in-psoriasis/2460917/Soligenix, Inc. will be expanding synthetic hypericin development under the research name SGX302 into psoriasis. The company made this move after the validation of synthetic hypericin's biologic activity in the positive pivotal Phase 3 FLASH (Fluorescent Light Activated S
- Dermala Scores New Patent Covering the Use of Human Microbiome to Prevent, Slow, and Reverse Skin Aginghttps://practicaldermatology.com/news/dermala-scores-new-patent-covering-the-use-of-human-microbiome-to-prevent-slow-and-reverse-skin-aging/2460910/Dermala has received issuance of a U.S. Patent to use the human microbiome to slow down the skin aging process. The newly patented technology uses novel microbiome formulations and delivery methods to restore biologically "younger" skin and gut microbiomes in older adult